Used to classify article posts by terms used for medical conditions. It’s mostly aimed at practitioners and physicians.

Cannabinoids in depressive disorders.

Authors: Ewa Poleszak, Sylwia Wośko, Karolina Sławińska, Aleksandra Szopa, Andrzej Wróbel, Anna Serefko
Life Sciences, 15 November 2018

Cannabis sativa is one of the most popular recreational and medicinal plants. Benefits from use of cannabinoid agents in epilepsy, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, and others have been suggested. It seems that the endocannabinoid system is also inv…

Current natural therapies in the treatment against glioblastoma.

Authors: José Ignacio Erices, Ángelo Torres, Ignacio Niechi, Isabel Bernales, Claudia Quezada
Phytotherapy Research, November 2018

Glioblastoma (GBM) is the most common and aggressive brain tumor, which causes the highest number of deaths worldwide. It is a highly vascularized tumor, infiltrative, and its tumorigenic capacity is exacerbated. All these hallmarks are therapeutic targets in GBM treatment, in…

Cannabis Use and Hypomania in Young People: A Prospective Analysis .

Authors: Steven Marwaha, Catherine Winsper, Paul Bebbington, Daniel Smith
Schizophrenia Bulletin, November 2018

Background: Cannabis use in young people is common and associated with psychiatric disorders. However, the prospective link between cannabis use and bipolar disorder symptoms has rarely been investigated. The study hypothesis was that adolescent cannabis use is associated with…

Appraising the “entourage effect”: Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer.

Authors: Sandra Blasco-Benito, Marta Seijo-Vila, Miriam Caro-Villalobos, Isabel Tundidor, et al
Biochemical Pharmacology, November 2018

Breast cancer is the second leading cause of death among women. Although early diagnosis and development of new treatments have improved their prognosis, many patients present innate or acquired resistance to current therapies. New therapeutic approaches are therefore warrante…

Effect of cannabidiolic acid and ∆9-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema in a rodent model of inflammatory pain.

Authors: Erin M. Rock, Cheryl L. Limebeer, Linda A. Parker
Psychopharmacology, November 2018

RATIONALE: Cannabidiol (CBD), a non-intoxicating component of cannabis, or the psychoactive Δ9-tetrahydrocannabiol (THC), shows anti-hyperalgesia and anti-inflammatory properties. OBJECTIVES: The present study evaluates the anti-inflammatory and anti-hyperalgesia effects of CB…

Cannabis in palliative care: current challenges and practical recommendations

Authors: Claude Cyr, Maria Fernanda Arboleda, Sunil Kumar Aggarwal, Lynda G. Balneaves, Paul Daeninck, Andrée Néron, Erin Prosk, Antonio Vigano
Annals of Palliative Medicine, October 2018

Pain and symptom control challenges are common in palliative care, and the search for other therapeutic strategies is ongoing. Unfortunately, patients and their caregivers are receiving little information or support from healthcare providers regarding the increasingly popular…

Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.

Authors: José A. Crippa, Francisco S. Guimarães, Alline C. Campos, Antonio W. Zuardi
Frontiers in Immunology, 21 September 2018

Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a compound that does not produce the typical subjective effects of marijuana. Objectives: The aim of the present review is to describe the main advances in the development of the experimental a…

Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV).

Authors: Antony J. Mersiades, Annette Tognela, Paul S. Haber, Martin Stockler, Nicholas Lintzeris, et al
BMJ open, 12 September 2018

INTRODUCTION: Chemotherapy-induced nausea and vomiting (CINV) remains an important issue for patients receiving chemotherapy despite guideline-consistent antiemetic therapy. Trials using delta-9-tetrahydrocannabinol-rich (THC) products demonstrate limited antiemetic effect, si…

Cannabinoids and spinal cord stimulation for the treatment of failed back surgery syndrome refractory pain.

Authors: Epifanio Mondello, Domenico Quattrone, Luigi Cardia, Giuseppe Bova, et al
Journal of Pain Research, 6 September 2018

OBJECTIVE: This study aimed to evaluate pain and its symptoms in patients with failed back surgery syndrome (FBSS) refractory to other therapies, treated with a combination of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), in association with spinal cord stimulation…

Cannabis use predicts risks of heart failure and cerebrovascular accidents: results from the National Inpatient Sample.

Authors: Aditi Kalla, Parasuram Krishnamoorthy, Akshaya Gopalakrishnan, Vincent Figueredo
Journal of Cardiovascular Medicine, September 2018

BACKGROUND: Cannabis for medicinal and/or recreational purposes has been decriminalized in 28 states as of the 2016 election. In the remaining states, cannabis remains the most commonly used illicit drug. Cardiovascular effects of cannabis use are not well established due to a…

Marijuana Use by Breastfeeding Mothers and Cannabinoid Concentrations in Breast Milk.

Authors: Kerri A. Bertrand, Nathan J. Hanan, Gordon Honerkamp-Smith, Brookie M. Best, Christina D. Chambers
Pediatrics, September 2018

BACKGROUND AND OBJECTIVE: Marijuana is the most commonly used recreational drug among breastfeeding women. With legalization of marijuana in several US states and a 1990 study in which authors documented psychomotor deficits in infants breastfed by mothers using marijuana, the…

Localization of cannabinoid receptors CB1, CB2, GPR55, and PPARα in the canine gastrointestinal tract.

Authors: Giorgia Galiazzo, Fiorella Giancola, Agnese Stanzani, Federico Fracassi, Chiara Bernardini, Monica Forni, Marco Pietra, Roberto Chiocchetti
Histochemistry and Cell Biology, August 2018

The endocannabinoid system (ECS) is composed of cannabinoid receptors, their endogenous ligands, and the enzymes involved in endocannabinoid turnover. Modulating the activity of the ECS may influence a variety of physiological and pathophysiological processes. A growing body o…